23andMe Holding Co. (MEHCQ)

OTCMKTS · Delayed Price · Currency is USD
3.590
-0.170 (-4.52%)
Jun 3, 2025, 9:30 AM EDT
Market Cap 100.87M
Revenue (ttm) 208.78M
Net Income (ttm) -390.37M
Shares Out 26.83M
EPS (ttm) -15.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 149,021
Average Volume 595,201
Open 3.570
Previous Close 3.760
Day's Range 3.530 - 3.656
52-Week Range 0.470 - 3.990
Beta 1.99
RSI 76.36
Earnings Date May 23, 2025

About 23andMe Holding Co.

23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how... [Read more]

Sector Healthcare
Founded 2006
Employees 582
Stock Exchange OTCMKTS
Ticker Symbol MEHCQ
Full Company Profile

Financial Performance

In 2023, 23andMe Holding Co.'s revenue was $219.64 million, a decrease of -26.66% compared to the previous year's $299.49 million. Losses were -$666.70 million, 113.9% more than in 2022.

Financial Statements

News

23andMe customers notified of bankruptcy

23andMe has filed for Chapter 11 bankruptcy protection in the U.S., which means your genetic data is for sale, and you only have until July 14 to file a claim. This filing will initiate the sale of al...

21 hours ago - TechCrunch

23andMe founder aims to restart auction with major corporate backing

The founder of 23andMe , Anne Wojcicki, has asked a U.S. judge to reopen an auction for the genetic testing company, saying she has the support of a Fortune 500 company with a current market capitaliz...

1 day ago - Reuters

23andMe to delist from Nasdaq, deregister with SEC

23andMe to delist from Nasdaq, deregister with SEC

6 days ago - CNBC

23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC

SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced its intention to file...

7 days ago - GlobeNewsWire

What Regeneron's Purchase Of 23andMe Means For Your Genetic Privacy

Regeneron Pharmaceuticals announced on Monday it will acquire bankrupt genomics firm 23andMe for $256 million through a bankruptcy auction, promising to maintain ethical standards in handling sensitiv...

12 days ago - Forbes

Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D, but the benefits are years away and the risks are immediate. Eylea franchise revenues dropped 26% year-over-year as biosi...

13 days ago - Seeking Alpha

Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal

Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.

15 days ago - Fox Business

Pharma giant Regeneron to buy 23andMe and its customers' data for $256M

Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction.

15 days ago - TechCrunch

Bankrupt DNA testing firm 23andMe to be purchased for $256m

Drugmaker Regeneron Pharmaceuticals will buy the genetic testing firm through a bankruptcy auction

15 days ago - The Guardian

Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million

Regeneron Pharmaceuticals is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction. The drugmaker is buying 23andMe's Personal Genome Service, Total Health ...

15 days ago - CNBC

23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.

Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year.

15 days ago - Business Insider

23andMe sells its most valuable asset. Regeneron promises keep your DNA private.

Regeneron said it will continue uninterrupted service of 23andMe's consumer genome services — such as connecting with living relatives with shared DNA — after its purchase closes as expected in the th...

15 days ago - Market Watch

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million

Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe's assets for $256 million after coming out on top at a bankruptcy auction for the once-sizzling DNA-testing startup.

15 days ago - WSJ

Regeneron to buy bankrupt genetic testing firm 23andMe for $256 million

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, the companies said on Monday.

15 days ago - Reuters

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness

Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe's customer data; stands ready to work with independent, cour...

15 days ago - GlobeNewsWire

Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale

Regeneron Commits to Comply with Company's Privacy Policy and All Applicable Law; No Changes to 23andMe's Privacy Policy or Consumer Genome Services

15 days ago - GlobeNewsWire

23andMe will have court-appointed overseer for genetic data in bankruptcy

Genetic testing company 23andMe agreed on Tuesday to allow a court-appointed overseer to take charge of ensuring customers' genetic data remains protected during the company's bankruptcy, settling a d...

4 weeks ago - Reuters

Congress has questions about 23andMe bankruptcy

3The leaders of the House Committee on Energy and Commerce said they are investigating how 23andMe's bankruptcy might affect customers' data.

6 weeks ago - TechCrunch

23andMe Provides Update Regarding Court-Supervised Sale Process

SAN FRANCISCO, April 18, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today provided additional informati...

6 weeks ago - GlobeNewsWire

23andMe bankruptcy under congressional investigation for customer data

The House Committee on Energy and Commerce sent a letter to 23andMe expressing concern that its genetic data is "at risk of being compromised." The embattled genetic testing company filed for Chapter ...

6 weeks ago - CNBC

US House committee seeks testimony from 23andMe co-founder after bankruptcy

A U.S. House committee on Monday asked 23andMe's co-founder to testify next month as it launched an investigation into the risk of genetic data being transferred to potential buyers amid the DNA testi...

7 weeks ago - Reuters

23andMe probe launched to prevent customer DNA data from being sold to China or other bad actors

Sen. Bill Cassidy is probing 23andMe, which recently filed for bankruptcy protection, to ensure the company does not sell customer data to China or other foreign adversaries.

7 weeks ago - Fox Business

Gulp Data Estimates 23andMe's Data Assets to Be Worth $289 Million Amid Bankruptcy Concerns

SAN JUAN, Puerto Rico--(BUSINESS WIRE)--Gulp Data, a leader in data valuation and collateralization, estimates that the market comparable value of 23andMe's data assets is approximately $289 million. ...

2 months ago - Business Wire

What's next for 23andMe and all that DNA data?

As 23AndMe files for bankruptcy, customers are left wondering what happens to their DNA data? On this episode of the Big Take podcast, we discuss what this means for millions of users' genetic data an...

2 months ago - Bloomberg Markets and Finance

US regulators tell 23andMe to protect genetic data

The US Federal Trade Commission (FTC) on Monday warned genetic testing firm 23andMe to honor its promise to protect people's personal information as it navigates bankruptcy.

2 months ago - TechXplore